EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 四環醫藥控股集團有限公司 | | 股份代號 | 00460 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月之中期現金股息 | | 公告日期 | 2025年8月29日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.0099 RMB | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.0109 HKD | | 匯率 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 截至二零二五年六月三十日止六個月 中期業績公告 四 環 醫 藥 控 股 集 團 有 限 公 司（「四環醫藥」或「本公司」）董 事（「董 事」）會（「董事會」） 欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月（「期 內」）的 未 經 審 核 綜 合 業 績 連 同 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 的 比 較 數 字。該 中 期 簡 明 綜 合 財 務 資 料 已 經 由 本 公 司 的 外 部 核 數 師 安 永 會 計師事務所根據國際審計和核證準則委員會頒佈的國際審閱業 ...

Summary of the Medical Aesthetics Industry Conference Call Industry Overview - The medical aesthetics market is experiencing overall poor performance in August 2025, with surgical procedures declining significantly and non-surgical projects showing slowed growth. Revenue growth is expected to remain flat compared to the same period last year, making it difficult to achieve over 5% growth [1][6][41]. - A large promotional campaign is planned from late August to mid-September to counteract the seasonal downturn, with expectations for growth in September and October, projecting a 25% growth in September 2023 and 14% in 2024 [1][7]. Financial Performance - Current profit margins have decreased to around 7-8%, prompting institutions to negotiate with suppliers, eliminate unprofitable product lines, and introduce high-margin products to mitigate the impact of declining profit margins [1][8]. - Sales of specific products like "少女针" (Youth Needle) and "乳白天使" (Milky Angel) have slowed, with sales volume for the Youth Needle down 16% year-on-year from January to July 2025, and Milky Angel down 2% [1][11][12]. Product Performance - The "苏颜萃" (Sculpture) product line was launched in July 2025, showing strong brand power and a significant profit margin, priced at 21,800 yuan with a procurement cost of over 4,000 yuan [1][13]. - The "HITTY" product line has seen a decline in sales, particularly HITTY 1.0 and HITTY 1.5, which dropped 23% and 13% year-on-year, respectively, due to competition and limited profit margins [1][19][20]. Market Dynamics - The overall market performance in August 2025 is disappointing, with revenue growth slowing across both national chains and light medical aesthetics institutions. Non-surgical project clinics have been less affected but still show minimal growth [1][5][6]. - The 4 mg purified collagen remains the most widely used category, but its growth rate is expected to slow to about 15% in 2025, down from 61% last year [2][28]. Competitive Landscape - The market for collagen products is shifting, with 10 mg and 17-type collagen showing faster growth rates compared to the 4 mg variant [2][29]. - The introduction of new products like "真爱苏菲" (True Love Sophie) is anticipated to replace the usage of "艾舒菲" (Ai Shufei) with a more favorable procurement price [1][23]. Strategic Considerations - The group plans to expand its store network by opening 5 to 6 new locations in 2025, while also focusing on eliminating outdated product lines and introducing new ones to stabilize profit margins [1][41]. - The competitive landscape indicates that small to medium-sized companies need to adapt, with a focus on light medical aesthetics brands showing promising growth [1][42]. Regulatory and Quality Control - The industry is under strict regulation, and the introduction of compliant new products is seen as beneficial for overall growth. Ensuring medical quality is a priority for leading institutions, which have built strong brand recognition and accumulated professional expertise over the years [1][41][44]. Conclusion - The medical aesthetics industry is facing significant challenges in growth and profitability, with a need for strategic adjustments and a focus on high-margin products to navigate the current market conditions.

国泰海通证券 | 研究所 葡 12-5 国泰海通证券2025消费品年会 2025年 9月2日-3日 上海 · 金茂君悦大酒店 联席首席分析 联席首席分 织服装 在线上游戏即时 7越田 杜服 家用电器 以用相 *议程内容更新于2025年8月25日15:40 9月2日上午 · 主会场 | 09:00-09:10 开场致辞 | | | --- | --- | | | 陈忠义 - 国泰海通证券副总裁、研究与机构业务委 | | | 员会总裁、政策和产业研究院院长 | | 09:10-09:40 | 长寿时代消费趋势 | | | 张教授-复旦大学人口研究所所长 | | 09:40-10:10 | 国货美妆如何逆袭? | | | 舒总-美妆商业评论主理人 | | 10:10-10:40 | 功能性保健品时代 | | | 杨总-仙乐健康董事 | | 10:40-11:10 | 超市调改解读与展望 | | | 知名超市专家 | | 11:10-12:00 | 圆桌论坛 | | | 新消费时代 | | | 警 猛-研究所所长助理、消费组长、食品饮料/美护 | | | 首席分析师 | | | 新消费持续高景气,强政策推动大机会 | ...

Investment Rating - The industry rating is "Strongly Outperforming the Market" [96] Core Insights - The report highlights the "Small Happiness" consumption trend, indicating that new consumption does not rely on overall economic growth but rather on the expansion of consumption behaviors among niche groups [3][12] - The tourism sector, particularly in Changbai Mountain, has seen significant growth, with July 2025 visitor numbers reaching 810,200, a 37.8% year-on-year increase, marking a historical high for the month [4][51] - The duty-free sector is expected to benefit from the upcoming Hainan Free Trade Port's closure, which will allow visa-free entry for individuals from 85 countries, significantly increasing the user base for duty-free shopping [4][45] - The report emphasizes the potential of the "trendy play" sector, supported by recent policies aimed at stimulating consumption and industry regulation, which may favor compliant leading enterprises [5][53] - In the education sector, advancements in AI+ education are noted, with several companies launching AI-driven educational products, indicating a potential revenue surge for key players [6][63] - The medical beauty industry is undergoing optimization through refined operations, with leading institutions expected to capture more market share as new products are launched [6][73] Summary by Sections New Consumption - New consumption is characterized by emotional value rather than cost-effectiveness, with a shift from heavy asset allocation to frequent "small happiness" purchases [3][12] - The youth demographic (ages 15-24) is projected to drive consumption trends as they enter the labor market, while the adult demographic's influence is expected to diminish [15] Duty-Free and Tourism - The duty-free industry is poised for growth with the Hainan Free Trade Port's upcoming closure, enhancing the attractiveness of the region for international tourists [42][45] - Changbai Mountain's tourism data indicates a strong recovery and growth potential, particularly in the summer season [4][51] Trendy Play - The trendy play sector is expected to benefit from consumption policies and industry self-regulation, with long-term prospects for cultural products expanding overseas [5][53] Education - The AI+ education sector is gaining traction, with several companies launching innovative products that are expected to see significant revenue growth [6][63] Medical Beauty - The medical beauty industry is experiencing a shift towards refined operations, with new product launches expected to enhance market dynamics [6][73]

Major Events - Xianjian Technology (01302) has entered the special review process for innovative medical devices for its nickel-titanium alloy arterial duct occluder [1] - Sunny Optical Technology (02382) signed a memorandum of understanding with GoerTek (002241.SZ) and GoerTek Optical to promote complementary advantages [1] - Fuhong Hanlin (02696) completed the first patient dosing in the U.S. for its HLX43 (targeted PD-L1 antibody conjugate) in an international multi-center Phase II clinical study for advanced non-small cell lung cancer [1] - Shanghai Pharmaceuticals (02607) received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYS 6036 injection in China [1] - Kaisa Group (01638) reached a strategic cooperation with CITIC City Construction for the Shenzhen Futian Jiayuan project [1] - Conant Optical (02276) has been included in the Hang Seng Composite Index [1] - China Railway (00390) is investigating the cause of the Qianzhazhuang Yellow River Bridge accident, which has resulted in 12 fatalities and 4 missing persons [1] - Dongfeng Motor Group (00489) plans to be privatized at a premium, while Lantu Automobile has applied for a listing introduction [1] - Baize Medical (02609) has been included in the Hang Seng Index series [1] - Zhongmiao Holdings (01471) plans to acquire 55% of Beijing Kechuang Rongxin Technology Co., Ltd. for 165 million yuan [1] - Huaxing Capital Holdings (01911) intends to establish a strategic cooperation framework with YZi Labs to support the application of Binance Coin and the BNB Chain ecosystem [1] - Sihuan Pharmaceutical (00460) received approval from the National Medical Products Administration for its self-developed innovative drug, Dirocitin [1] - China Tongru (01763) successfully obtained a radiation safety license for its radiation source R&D and production base [1] Operating Performance - Cathay Pacific (00293) and Hong Kong Express carried approximately 3.2 million passengers in July, setting a new monthly record for the year [2] - CSPC Pharmaceutical Group (01093) reported a mid-year profit attributable to shareholders of 2.548 billion yuan, a decrease of 15.64% year-on-year [2] - TCL Electronics (01070) reported a mid-year net profit of 1.09 billion HKD, an increase of 67.78% year-on-year [2] - Chongqing Bank (01963) reported a mid-year net profit of 3.19 billion yuan, a year-on-year increase of 5.39%, indicating stable profitability [2] - Shenwan Hongyuan Hong Kong (00218) reported a mid-year profit attributable to ordinary shareholders of 60.134 million HKD, turning from loss to profit [2] - Times Electric (03898) reported a mid-year net profit of 1.6715 billion yuan, a year-on-year increase of 12.93% [2] - CIFI Holdings Group (00884) reported mid-year revenue of 12.281 billion yuan, delivering approximately 15,000 property units in the first half of the year [2] - CRRC (01766) reported a mid-year net profit of 7.246 billion yuan, a year-on-year increase of 72.48% [2] - China Tobacco Hong Kong (06055) reported a mid-year profit attributable to shareholders of 706 million HKD, an increase of 9.79% year-on-year [2] - Vanke Enterprises (02202) reported mid-year revenue of 105.323 billion yuan, maintaining operational efficiency among industry peers [2] - Greentown Management Holdings (09979) reported a mid-year profit attributable to shareholders of 256 million yuan [2] Additional Operating Performance - Goldwind Technology (02208) reported a mid-year profit attributable to shareholders of 1.488 billion yuan, an increase of 7.26% year-on-year [3] - Zhouliufu (06168) reported a mid-year net profit of 415 million yuan, an increase of approximately 11.9%, with a mid-year dividend of 0.45 yuan per share [3] - Zhejiang Huhangyong (00576) reported a mid-year profit attributable to shareholders of 2.787 billion yuan, a year-on-year increase of 4% [3] - Dongfeng Motor Group (00489) reported a mid-year profit attributable to shareholders of 55 million yuan, a decrease of 91.96% year-on-year [3] - Zhaojin Mining (01818) reported a mid-year profit attributable to shareholders of approximately 1.44 billion yuan, a year-on-year increase of approximately 160.44% [3]

Core Viewpoint - The approval of the innovative ALK inhibitor, Dirocitinib (formerly known as "Dazatinib"), by the National Medical Products Administration (NMPA) in China marks a significant advancement for the company in the oncology field, particularly for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) [1][2]. Group 1: Product Approval and Significance - The product is the third class 1 innovative drug approved for the company and the second innovative oncology drug, showcasing the company's continuous progress in targeted therapies from breast cancer to lung cancer [1]. - Dirocitinib has four core advantages: rapid onset of action, superior tumor suppression, prolonged relief for patients, and significant survival benefits, achieving the goal of chronic disease management [1]. Group 2: Clinical Breakthroughs - Dirocitinib successfully addresses clinical challenges by controlling brain metastases and ensuring safety, effectively penetrating the blood-brain barrier [2]. - The safety profile of Dirocitinib shows significant advantages, with adverse reactions primarily being mild gastrointestinal issues, which can be managed through symptomatic treatment or dose adjustments [2].

Core Viewpoint - The approval of the innovative ALK inhibitor drug, Dirocitinib (formerly known as "Dahisitinib"), by the National Medical Products Administration (NMPA) in China marks a significant advancement for the company in the oncology field, particularly for treating ALK-positive advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Product Approval and Significance - The drug Dirocitinib is the third innovative drug approved for market by the company's subsidiary, Xuan Zhu Bio-Tech, and the second innovative oncology drug, showcasing the company's continuous progress in targeted therapies from breast cancer to lung cancer [1] - Dirocitinib has four core advantages: rapid onset of action, superior tumor suppression, prolonged relief for patients, and significant survival benefits, achieving the goal of chronic disease management [1] Group 2: Clinical Breakthroughs - Dirocitinib successfully addresses clinical challenges by controlling brain metastases and ensuring safety, effectively penetrating the blood-brain barrier and compensating for existing therapies' shortcomings in central nervous system protection [2] - The drug demonstrates significant safety advantages, with adverse reactions primarily being mild gastrointestinal issues, which can be managed through symptomatic treatment or dose adjustments, leading to improved long-term medication adherence among patients [2]

Core Points - The Hang Seng Index constituents will increase from 85 to 88 stocks, with the addition of China Telecom, JD Logistics, and Pop Mart [3] - The changes will take effect after the market closes on September 5, 2025, and will be implemented on September 8, 2025 [2][6] - The Hang Seng Composite Index will also see an increase in constituents from 502 to 504 stocks [5] Index Changes - The Hang Seng Technology Index will maintain its constituent count at 30 stocks [4] - The Hang Seng China Enterprises Index will keep 50 stocks, adding Pop Mart and removing J&T Express [5] - The Hang Seng Biotechnology Index will decrease from 50 to 30 stocks, adding InnoCare Pharma and removing 21 stocks including WuXi AppTec and Sinovac Biotech [5] Market Performance - The Hong Kong stock market has shown relatively weak performance compared to the A-share market, with the Hang Seng Index up 0.27% and the Hang Seng Technology Index up 1.89% this week [7] - Notable stock performances include Anta Sports up 11.53% and NIO up 27.75%, while stocks like Bilibili and Meituan saw declines [7] - Southbound trading through the Stock Connect continues to show strong interest, with net purchases exceeding HKD 50 billion on August 22, 2023, and a total of approximately HKD 900 billion in net purchases for August 2023 [8]

Core Viewpoint - The approval of the innovative ALK inhibitor, Dirocitinib (formerly known as "Dahitinib"), by the National Medical Products Administration (NMPA) in China marks a significant milestone for Xuan Bamboo Biotechnology and provides a breakthrough treatment option for patients with ALK-positive advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Product Approval and Significance - Dirocitinib is the third innovative drug approved for Xuan Bamboo Biotechnology and the second innovative oncology drug, showcasing the company's continuous advancement in targeted therapies from breast cancer to lung cancer [1] - The approval represents an important research and development milestone for Xuan Bamboo's innovative drug pipeline, contributing to the acceleration of cancer prevention and treatment goals under the "Healthy China 2030" initiative [2] Group 2: Drug Advantages - Dirocitinib has four core advantages: rapid onset of action, superior tumor suppression, prolonged relief for patients, and significant survival benefits, achieving the goal of chronic disease management [1] - The drug effectively penetrates the blood-brain barrier, addressing existing therapies' shortcomings in central nervous system protection, while demonstrating a favorable safety profile with manageable side effects [2] Group 3: Clinical Impact - In pivotal Phase III clinical trials, Dirocitinib showed significant efficacy compared to existing first- and second-generation ALK inhibitors, particularly against resistant mutations such as G1202R and I1171N [1] - The drug's safety profile includes primarily mild gastrointestinal reactions, with reduced risks of pleural effusion and hepatotoxicity, enhancing long-term medication adherence among patients [2]